Comparison of up-front treatments for newly diagnosed immune thrombocytopenia -a systematic review and network meta-analysis.

ABSTRACT: Corticosteroids such as prednisolone and dexamethasone have been established as up-front therapy for the treatment of newly diagnosed immune thrombocytopenia. Recent studies have indicated that other treatments such as rituximab or thrombopoietin receptor agonist can also be effective choices. We performed a systematic review and network meta-analysis to establish a clinically meaningful hierarchy of efficacy and safety of treatments for newly diagnosed primary immune thrombocytopenia in adults. Randomized controlled trials evaluating medical treatments for newly diagnosed immune thrombocytopenia were included. Reviewers independently extracted data and assessed the risk of bias. The main outcome was the sustained response (platelet count >30×10⁹/L for 3-6 months after completio

SUBMITTER: Arai Y 

PROVIDER: S-EPMC5777203 | biostudies-literature | 2018 Jan

REPOSITORIES: biostudies-literature